Is adagratib from Bristol-Myers Squibb?

Adagrasib (Adagrasib) is produced by Mirati Therapeutics, Inc., Bristol-Myers Squibb. This company has a deep history and outstanding achievements in the field of pharmaceutical research and development, and adagrasib is undoubtedly one of its outstanding results in recent years. Adagarasib has made exciting progress in clinical trials for patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors with KRAS G12C mutations.

As an anti-tumor drug belonging to theRAS GTPase family, adagrasib is in the form of film-coated tablets and provides patients with a more convenient treatment method through oral administration. It is specifically designed to treat adult patients with locally advanced or metastatic non-small cell lung cancer who carry KRAS G12C mutations, bringing them hope of life. Adagrasiib is not without side effects. The use of adagrasiib may result in prolongation of the QTc interval, and this change is closely related to drug concentration. In patients receiving adagrasiib 600 mg twice daily, the mean QTcF change from baseline reached 18 ms. In addition, adagrasib may also cause serious gastrointestinal adverse reactions, liver toxicity, interstitial lung disease/pneumonitis, etc. Therefore, when using adagrasib, the doctor's instructions must be strictly followed to ensure patient safety.

Bristol-Myers Squibb is currently engaged in the clinical development of adagrasib and has entered the Phase III treatment stage for metastatic colorectal cancer. According to GlobalData, the Phase III drug for the treatment of metastatic colorectal cancer has a high PTSR indication benchmark, which means that adagrasib is expected to enter the pre-registration stage in the future.